HALO
Halozyme Therapeutics IncNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$7.53B
P/E Ratio
24.84
EPS
$2.56
Beta
1.03
52W High
$82.22
52W Low
$47.50
50-Day MA
$69.71
200-Day MA
$67.36
Dividend Yield
—
Profit Margin
22.70%
Forward P/E
4.75
PEG Ratio
-2.50
About Halozyme Therapeutics Inc
Halozyme Therapeutics, Inc. is a biopharmaceutical technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company is headquartered in San Diego, California.
Fundamentals
| Revenue (TTM) | $1.40B |
| Gross Profit (TTM) | $1.09B |
| EBITDA | $897.84M |
| Operating Margin | 56.30% |
| Return on Equity | 153.60% |
| Return on Assets | 22.20% |
| Revenue/Share (TTM) | $11.65 |
| Book Value | $0.41 |
| Price-to-Book | 156.52 |
| Price-to-Sales (TTM) | 5.40 |
| EV/Revenue | 6.9 |
| EV/EBITDA | 16.82 |
| Quarterly Earnings Growth (YoY) | 36.20% |
| Quarterly Revenue Growth (YoY) | 51.60% |
| Shares Outstanding | $118.47M |
| Float | $116.53M |
| % Insiders | 1.08% |
| % Institutions | 107.53% |
Analyst Ratings
Consensus ($84.89 target)
2
Strong Buy4
Buy2
Hold1
SellData last updated: 4/8/2026